Of note, it has been demonstrated that targeting for the PML with ATO could lead to loss of self-renewal capability of LSCs, which is closely linked to chemotherapy resistance and disease relapse, in CML [18], suggesting that ATO would be a promising candidate for a LSCs-targeted therapy [17]. This evidence concerns the gene PML and chronic myelogenous leukemia, BCR-ABL1 positive.